Research Spotlight: Genaro Camele, Co-founder of Nubaio
At Nubaio, we believe the future of healthcare lies at the intersection of science and scalable technology. Today, we’re proud to highlight the groundbreaking doctoral research of our co-founder, Genaro Camele, whose work is transforming how researchers approach multi-omics analysis in oncology.
His thesis — “Accelerating Feature Selection Processes in Big Data Environments for Oncological Biomarker Identification” — introduces a cloud-native framework designed to make biomarker discovery faster, scalable, and more accessible for researchers worldwide.
Key Innovations in Genomic & Epigenomic Data Processing
As multi-omics research grows increasingly data-intensive, infrastructure becomes the limiting factor. Genaro’s work tackles this challenge by integrating big data architecture and high-performance computing directly into the bioinformatics pipeline.
Here are the key components of the framework:
Multiomix
An open, cloud-based platform for multi-omics biomarker discovery and correlation analysis. Researchers can analyze mRNA, miRNA, DNA methylation, and more — without needing deep programming knowledge.
PELADO
A custom load-balancing algorithm built for Apache Spark, PELADO dynamically distributes processing tasks across clusters — reducing runtime during complex feature selection.
Modulector & BioAPI
These integrated tools streamline access to data on genes, modulators, and pathways — providing essential context for oncological biomarker interpretation.
GGCA (Gene GEM Correlation Analysis)
A high-performance correlation analysis library, developed in-house to support scalable matrix-based comparisons across large omics datasets.
Why This Research Matters
With global cancer incidence projected to exceed 35 million cases by 2050 (IARC, 2022), the need for scalable, reproducible tools in precision oncology is more urgent than ever.
But the bottleneck in turning raw biological data into actionable insights isn’t just about smarter algorithms — it’s about robust infrastructure.
Genaro’s research helps solve this by:
-
- Accelerating feature selection across high-dimensional omics datasets
-
- Supporting open and reproducible research workflows
-
- Reducing computational costs for large-scale biomarker discovery
-
- Bridging research and clinical insight for real-world precision oncology applications
By advancing the computational foundation of multi-omics research, this work paves the way for faster, data-driven decisions in cancer diagnosis and treatment.
Awards & Recognition
This research has been recognized nationally and internationally for its scientific and technological impact:
First Place – Innova CONICET–AWS (2022)
Winner in the Health category, selected among Argentina’s top 14 innovation projects.
Link: https://www.conicet.gov.ar/innova-conicet
Special Mention – HIVE 2024 International Bioinformatics Hackathon
Praised for its reproducible and scalable approach to omics data analysis.
Published Work
Featured in peer-reviewed journals such as Oxford Bioinformatics and presented at national and international conferences.
Explore the Full Research
Doctoral Thesis (in Spanish):
Partner With Us to Shape the Future of Precision Oncology
Whether you’re a funder, healthcare innovator, or research partner, Nubaio is building scalable infrastructure and open tools that are ready to grow — and designed to make a lasting impact in cancer care.
Genaro Camele’s research is just one example of how we combine scientific depth with engineering scale to accelerate discovery and deliver real-world outcomes.
Let’s explore how we can work together to bring faster, smarter, and more accessible precision oncology solutions to life.
Contact us: ceo-office@nubaio.com
We’re building more than tools — we’re building a healthier future.
